Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | HTR1B | P28222 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR1E | P28566 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12966393 | 1.00 | TACR1 (0.62) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL6423830 | 1.00 | TACR1 (0.62) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL28537587 | 0.99 | TACR1 (0.61) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL6240398 | 0.99 | TACR1 (0.61) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL16278133 | 0.99 | TACR1 (0.61) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL6243067 | 0.99 | TACR1 (0.61) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL1720662 | 0.99 | TACR1 (0.61) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL12966390 | 0.99 | TACR1 (0.61) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL6240394 | 0.99 | TACR1 (0.61) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL6243285 | 0.99 | TACR1 (0.61) | TACR1MAPTKDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949952-B2 | Methods and compositions for transdermal delivery | SPRAYABLE HOLDINGS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150258065-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | SPRAYABLE HOLDINGS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-6841555-B2 | Lavendamycin analogs, quinoline-5,8-diones and methods of using them | BALL STATE UNIVERSITY (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | BALL STATE UNIVERSITY | 2004-12-09 | — | — | US | disclosed |
| US-6444684-B1 | ANTIBIOTIC AND ANTI-HIV REVERSE TRANSCRIPTASE (HIV-RT) ACTIVITY; TREATING HIV INFECTION AND ALSO WITH AZT; ANTITUMOR | BALL STATE UNIVERSITY | 2002-09-03 | — | — | US | disclosed |
| US-6030983-A | ANTITUMOR AND -CARCINOGENIC AGENTS; ANTIBIOTICS; BACTERICIDES; VIRICIDES; PARACITICIDES; ENZYME INHIBITORS; POLYMERASES; FARNESYL-PROTEIN TRANSFERASE; RAS PROTEINS | BALL STATE UNIVERSITY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5712289-A | ANTITUMOR AGENTS, INTERMEDIATES FOR LAVENDAMYCINS | BALL STATE UNIVERSITY (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0701557-A4 | LAVENDAMYCIN ANALOGS, THEIR USE AND PREPARATION | BEHFOROUZ MOHAMMAD (US) | 1997-07-09 | — | — | EP | disclosed |
| US-5646150-A | ADMINISTERING AS ANTITUMOR AGENT, ANTIPROTOZOA AGENT, VIRICIDE, PARASITICIDE, OR BACTERICIDE | BALL STATE UNIVERSITY (US) | 1997-07-08 | — | — | US | disclosed |
| US-5525611-A | ANTITUMOR AGENT, BACTERICIDES, VIRICIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1996-06-11 | — | — | US | disclosed |
| EP-0701557-A1 | LAVENDAMYCIN ANALOGS, THEIR USE AND PREPARATION | BEHFOROUZ, Mohammad (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994029308-A1 | LAVENDAMYCIN ANALOGS, THEIR USE AND PREPARATION | BEHFOROUZ MOHAMMAD (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258065-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | MTNR1A, MTNR1B, CYP27B1 | TACR1 1032/4885MAPT 2224/4885KDM4E 2385/4885 |
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | LSS, CYP51A1, COX5A | TACR1 4381/4885MAPT 4560/4885KDM4E 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.